TheEdgeResearch
Home / Stocks / CAMRF

Camurus AB (CAMRF)

OTC Healthcare Medical - Pharmaceuticals
$58.51 ▲ +0.00%
Market Cap
$3.48B
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
0.52
52-Wk Range
54-71
CEO
Sven Fredrik Tiberg
Country
SE
Currency
USD

Camurus AB operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Lund, SN, SE. The stock last traded at $58.51, up 0.00% on the session, giving a market capitalisation of $3.48B. On trailing twelve-month figures it carries a trailing P/E of 54.70, a net margin of 29.9%. Its beta of 0.52 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
54.70
Price / Sales
16.36
Price / Book
7.92
EV / EBITDA
37.43
Gross margin
92.5%
Operating margin
36.3%
Net margin
29.9%
Return on equity
Debt / equity
0.02
Current ratio
10.01
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
285
IPO date
2017-12-11
Headquarters
Lund, SN, SE
About Camurus AB

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.

Comparable companies

Camurus AB is most often compared with the following Healthcare names:

AKBLFAMBBYGLPGFGNNSFINCPFLABFFLVZPFSHJBFSNPHFTLPPF
More research on CAMRF
CAMRF technical analysis CAMRF TheEdge Score Compare against peers
Open full interactive analysis & DCF →